HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HIGHTIDE-B

2.490

-0.150-5.68%

Volume:731.00K

Turnover:1.87M

Market Cap:1.42B

PE:-2.95

High:2.640

Open:2.640

Low:2.490

Close:2.640

52wk High:4.700

52wk Low:0.990

Shares:571.00M

HK Float Shares:571.00M

Volume Ratio:3.45

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.845

ROE:-62.13%

ROA:-35.29%

PB:3.97

PE(LYR):-2.95

PS:36.62

Loading ...

Overview Company News Filings

HIGHTIDE-B Completes Phase IIb Trial of HTD1801 for Metabolic Dysfunction-Associated Steatohepatitis

HighTide Therapeutics (2511) Completes Phase IIb Trial for HTD1801 in MASH Treatment

Bulletin Express

Hightide Therapeutics Completes Phase IIb Trial of HTD1801 for MASH Treatment

HighTide Therapeutics (02511) Announces January 2026 Monthly Return

Bulletin Express

HighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio

Bulletin Express

HighTide Therapeutics Appoints Chief Medical Officer

MT Newswires Live

HIGHTIDE-B (02511) Appoints Dr. Filip Surmont as Chief Medical Officer to Strengthen CKM Disease Portfolio

HighTide Therapeutics Appoints Dr. Filip Surmont as Chief Medical Officer

Huatai Securities International Initiates Coverage on HIGHTIDE-B (02511) with "Buy" Rating, Sets Target Price at HK$5.78

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

HighTide Therapeutics (02511) Releases Monthly Return for November 2025

Bulletin Express

HighTide Therapeutics (2511.HK) Reports Positive Phase III HARMONY Trial Results for HTD1801 in T2DM

Bulletin Express

HIGHTIDE-B (02511) Announces Positive Phase III Clinical Results for HTD1801 vs. Dapagliflozin, Demonstrating Superior Glycemic Control and Cardiometabolic Benefits

Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial

Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast

HighTide Therapeutics (2511) Announces HTD1801 Renal Benefit Findings at ASN 2025

Bulletin Express

2025 ASN Breakthrough Session: HIGHTIDE-B (02511) Presents Renal Benefits Data for HTD1801

HighTide Therapeutics Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting

HighTide Therapeutics, Inc. (02511) Reports No Changes in Share Capital for October 2025

Bulletin Express

HighTide Therapeutics (2511) Announces Positive 52-Week Results from Phase III Trials of HTD1801 for Type 2 Diabetes

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02511/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02511","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02511\",,,,,undefined,":{"symbol":"02511","market":"HK","secType":"STK","nameCN":"HIGHTIDE-B","latestPrice":2.49,"timestamp":1771834081451,"preClose":2.64,"halted":0,"volume":731000,"delay":0,"changeRate":-0.05681818181818178,"floatShares":571000000,"shares":571000000,"eps":-0.84452,"marketStatus":"Not Yet Opened","change":-0.15,"latestTime":"02-23 16:08:01","open":2.64,"high":2.64,"low":2.49,"amount":1873615,"amplitude":0.056818,"askPrice":2.49,"askSize":1500,"bidPrice":2.48,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.559,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":0,"adr":0,"listingDate":1703174400000,"exchange":"SEHK","adjPreClose":2.64,"openAndCloseTimeList":[[1771810200000,1771819200000],[1771822800000,1771833600000]],"volumeRatio":3.445791245025515,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02511\",,,,,undefined,":{"symbol":"02511","floatShares":571000000,"roa":"-35.29%","roe":"-62.13%","lyrEps":-0.84452,"volumeRatio":3.445791245025515,"shares":571000000,"dividePrice":0,"high":2.64,"amplitude":0.056818,"preClose":2.64,"low":2.49,"week52Low":0.99,"pbRate":"3.97","psRate":"36.62","week52High":4.7,"institutionHeld":0,"latestPrice":2.49,"committee":0.142857,"eps":-0.84452,"divideRate":0,"volume":731000,"delay":0,"ttmEps":-0.559,"open":2.64,"prevYearClose":2.95,"prevWeekClose":2.64,"prevMonthClose":2.68,"prevQuarterClose":2.95,"fiveDayClose":2.63,"twentyDayClose":2.99,"sixtyDayClose":2.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02511\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02511","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post Market","dateTimestamp":1743091200000,"actualEps":null},{"market":"HK","date":"2024-08-28","symbol":"02511","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724774400000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-27","symbol":"02511","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711503000000,"name":null,"time":"","dateTimestamp":1711468800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02511\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02511\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02511\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02511","date":"2026-02-20","current":-4.454383,"percent":0.344633,"low":-9.095359,"twenty":-5.677229,"median":-3.125093,"eighty":-0.885389,"high":-0.503695,"avg":-3.459628,"sd":2.532794,"marketCap":1508299763},"quantilePoints":[{"date":"2023-12-22","current":-8.734639,"twenty":-8.492642,"median":-8.129647,"eighty":-8.127643,"marketCap":6372860869},{"date":"2023-12-29","current":-9.095359,"twenty":-8.98365,"median":-8.695581,"eighty":-8.129647,"marketCap":6671427857},{"date":"2024-01-05","current":-8.537988,"twenty":-8.784441,"median":-8.544038,"eighty":-8.248369,"marketCap":6218429669},{"date":"2024-01-12","current":-8.363907,"twenty":-8.685299,"median":-8.537988,"eighty":-8.346736,"marketCap":6094884709},{"date":"2024-01-19","current":-8.1349,"twenty":-8.659812,"median":-8.456167,"eighty":-8.207816,"marketCap":5919862682},{"date":"2024-01-26","current":-8.649584,"twenty":-8.650972,"median":-8.460912,"eighty":-8.207816,"marketCap":6269906736},{"date":"2024-02-02","current":-8.361984,"twenty":-8.650972,"median":-8.483943,"eighty":-8.264989,"marketCap":6053703055},{"date":"2024-02-09","current":-8.504973,"twenty":-8.597346,"median":-8.473421,"eighty":-8.275661,"marketCap":6187543429},{"date":"2024-02-16","current":-8.602173,"twenty":-8.63062,"median":-8.476958,"eighty":-8.294295,"marketCap":6259611322},{"date":"2024-02-23","current":-8.036159,"twenty":-8.595019,"median":-8.473421,"eighty":-8.208635,"marketCap":5816908548},{"date":"2024-03-01","current":-7.945863,"twenty":-8.576687,"median":-8.451284,"eighty":-8.127643,"marketCap":5755136068},{"date":"2024-03-08","current":-6.052653,"twenty":-8.560192,"median":-8.40877,"eighty":-7.978802,"marketCap":4385846091},{"date":"2024-03-15","current":-5.695388,"twenty":-8.551566,"median":-8.362945,"eighty":-7.867218,"marketCap":4123313050},{"date":"2024-03-22","current":-4.312815,"twenty":-8.548208,"median":-8.27805,"eighty":-6.066123,"marketCap":3119510248},{"date":"2024-03-28","current":-2.992001,"twenty":-8.543906,"median":-8.212744,"eighty":-5.745595,"marketCap":3042294647},{"date":"2024-04-05","current":-2.73463,"twenty":-8.539468,"median":-8.197001,"eighty":-5.576119,"marketCap":2779761607},{"date":"2024-04-12","current":-2.176341,"twenty":-8.534781,"median":-8.129647,"eighty":-4.493311,"marketCap":2213513872},{"date":"2024-04-19","current":-2.517594,"twenty":-8.523109,"median":-8.043912,"eighty":-4.309916,"marketCap":2558410219},{"date":"2024-04-26","current":-2.586635,"twenty":-8.508057,"median":-7.951497,"eighty":-2.864821,"marketCap":2625330406},{"date":"2024-05-03","current":-2.649329,"twenty":-8.498668,"median":-7.924262,"eighty":-2.751198,"marketCap":2687102886},{"date":"2024-05-10","current":-3.422806,"twenty":-8.484817,"median":-7.769212,"eighty":-2.737043,"marketCap":3479849715},{"date":"2024-05-17","current":-3.275714,"twenty":-8.477244,"median":-6.276091,"eighty":-2.747016,"marketCap":3325418515},{"date":"2024-05-24","current":-2.698739,"twenty":-8.474688,"median":-5.875073,"eighty":-2.745416,"marketCap":2733432247},{"date":"2024-05-31","current":-2.594452,"twenty":-8.468417,"median":-5.713034,"eighty":-2.710462,"marketCap":2630478113},{"date":"2024-06-07","current":-2.277412,"twenty":-8.457116,"median":-5.462224,"eighty":-2.655805,"marketCap":2306172592},{"date":"2024-06-14","current":-2.08615,"twenty":-8.451368,"median":-5.115854,"eighty":-2.588198,"marketCap":2110559738},{"date":"2024-06-21","current":-1.830485,"twenty":-8.444904,"median":-4.331734,"eighty":-2.536299,"marketCap":1848026698},{"date":"2024-06-28","current":-0.719236,"twenty":-8.417702,"median":-4.312815,"eighty":-2.477957,"marketCap":725826641},{"date":"2024-07-05","current":-0.596943,"twenty":-8.40877,"median":-4.051691,"eighty":-2.463651,"marketCap":602281681},{"date":"2024-07-12","current":-0.636823,"twenty":-8.366276,"median":-3.549353,"eighty":-2.277412,"marketCap":643463335},{"date":"2024-07-19","current":-0.560394,"twenty":-8.363907,"median":-3.496298,"eighty":-2.190964,"marketCap":566247734},{"date":"2024-07-26","current":-0.517715,"twenty":-8.361984,"median":-3.220684,"eighty":-2.08615,"marketCap":525066081},{"date":"2024-08-02","current":-0.75671,"twenty":-8.318662,"median":-2.992001,"eighty":-1.873562,"marketCap":767008295},{"date":"2024-08-09","current":-0.776926,"twenty":-8.27805,"median":-2.863181,"eighty":-0.894876,"marketCap":792746828},{"date":"2024-08-16","current":-0.766537,"twenty":-8.266106,"median":-2.770601,"eighty":-0.773016,"marketCap":782451415},{"date":"2024-08-23","current":-0.652832,"twenty":-8.212744,"median":-2.747107,"eighty":-0.75671,"marketCap":669201868},{"date":"2024-08-30","current":-1.100172,"twenty":-8.205896,"median":-2.728047,"eighty":-0.729206,"marketCap":725826641},{"date":"2024-09-06","current":-0.912468,"twenty":-8.188106,"median":-2.679629,"eighty":-0.740924,"marketCap":602281681},{"date":"2024-09-13","current":-0.656825,"twenty":-8.1349,"median":-2.649329,"eighty":-0.723174,"marketCap":432407361},{"date":"2024-09-20","current":-0.691774,"twenty":-8.130698,"median":-2.594452,"eighty":-0.718911,"marketCap":458145894},{"date":"2024-09-27","current":-0.788079,"twenty":-8.126975,"median":-2.574831,"eighty":-0.711909,"marketCap":525066081},{"date":"2024-10-04","current":-0.892575,"twenty":-8.081521,"median":-2.538273,"eighty":-0.714203,"marketCap":591986268},{"date":"2024-10-10","current":-0.882415,"twenty":-8.045462,"median":-2.524212,"eighty":-0.716377,"marketCap":581690854},{"date":"2024-10-18","current":-0.879542,"twenty":-8.029599,"median":-2.476753,"eighty":-0.71826,"marketCap":576543148},{"date":"2024-10-25","current":-0.879598,"twenty":-7.992455,"median":-2.46526,"eighty":-0.719628,"marketCap":576543148},{"date":"2024-11-01","current":-0.933943,"twenty":-7.949243,"median":-2.40723,"eighty":-0.720238,"marketCap":612577094},{"date":"2024-11-08","current":-0.972706,"twenty":-7.937223,"median":-2.272633,"eighty":-0.721432,"marketCap":633167921},{"date":"2024-11-15","current":-0.836682,"twenty":-7.912537,"median":-2.191611,"eighty":-0.725587,"marketCap":540509201},{"date":"2024-11-22","current":-0.837164,"twenty":-7.876462,"median":-2.165315,"eighty":-0.733893,"marketCap":540509201},{"date":"2024-11-29","current":-0.781798,"twenty":-7.785116,"median":-2.08615,"eighty":-0.746636,"marketCap":504475254},{"date":"2024-12-06","current":-0.799637,"twenty":-7.200158,"median":-1.899521,"eighty":-0.755806,"marketCap":514770668},{"date":"2024-12-13","current":-0.768352,"twenty":-6.314044,"median":-1.830485,"eighty":-0.757354,"marketCap":494179841},{"date":"2024-12-20","current":-0.917454,"twenty":-6.072858,"median":-1.096301,"eighty":-0.757354,"marketCap":586838561},{"date":"2024-12-27","current":-1.047032,"twenty":-6.052653,"median":-1.059897,"eighty":-0.758321,"marketCap":669201868},{"date":"2025-01-03","current":-0.89313,"twenty":-5.910589,"median":-1.030203,"eighty":-0.759127,"marketCap":571395441},{"date":"2025-01-10","current":-0.872296,"twenty":-5.819219,"median":-1.016579,"eighty":-0.765095,"marketCap":555952321},{"date":"2025-01-17","current":-0.928085,"twenty":-5.745595,"median":-0.982343,"eighty":-0.767989,"marketCap":591986268},{"date":"2025-01-24","current":-0.890226,"twenty":-5.702446,"median":-0.971737,"eighty":-0.768352,"marketCap":571395441},{"date":"2025-01-28","current":-0.909941,"twenty":-5.677229,"median":-0.965955,"eighty":-0.76868,"marketCap":586838561},{"date":"2025-02-07","current":-0.962836,"twenty":-5.576119,"median":-0.960006,"eighty":-0.770428,"marketCap":617724801},{"date":"2025-02-14","current":-0.916884,"twenty":-5.437951,"median":-0.957687,"eighty":-0.772342,"marketCap":586838561},{"date":"2025-02-21","current":-1.079861,"twenty":-5.295856,"median":-0.96114,"eighty":-0.773201,"marketCap":694940401},{"date":"2025-02-28","current":-0.922924,"twenty":-4.99937,"median":-0.960573,"eighty":-0.77414,"marketCap":591986268},{"date":"2025-03-07","current":-0.807326,"twenty":-4.493311,"median":-0.957265,"eighty":-0.775085,"marketCap":519918374},{"date":"2025-03-14","current":-0.966841,"twenty":-4.332382,"median":-0.951297,"eighty":-0.775904,"marketCap":622872508},{"date":"2025-03-21","current":-1.151073,"twenty":-4.329727,"median":-0.958109,"eighty":-0.776927,"marketCap":741269761},{"date":"2025-03-28","current":-1.305593,"twenty":-4.323383,"median":-0.961988,"eighty":-0.77695,"marketCap":839076188},{"date":"2025-04-03","current":-1.964669,"twenty":-4.312815,"median":-0.968609,"eighty":-0.77703,"marketCap":803042242},{"date":"2025-04-11","current":-1.804502,"twenty":-4.298321,"median":-0.972706,"eighty":-0.779537,"marketCap":730974348},{"date":"2025-04-17","current":-2.094006,"twenty":-4.101017,"median":-0.982343,"eighty":-0.781346,"marketCap":849371602},{"date":"2025-04-25","current":-2.153289,"twenty":-3.838494,"median":-0.984395,"eighty":-0.781962,"marketCap":875110135},{"date":"2025-05-02","current":-2.275118,"twenty":-3.638788,"median":-0.998444,"eighty":-0.782191,"marketCap":926587202},{"date":"2025-05-09","current":-3.363784,"twenty":-3.551198,"median":-1.021661,"eighty":-0.782445,"marketCap":1379585390},{"date":"2025-05-16","current":-3.99636,"twenty":-3.977419,"median":-1.026921,"eighty":-0.783805,"marketCap":1652413844},{"date":"2025-05-23","current":-3.475525,"twenty":-3.891419,"median":-1.043315,"eighty":-0.788891,"marketCap":1441357870},{"date":"2025-05-30","current":-2.595234,"twenty":-3.819658,"median":-1.05978,"eighty":-0.79364,"marketCap":1081018402},{"date":"2025-06-06","current":-3.217297,"twenty":-3.690833,"median":-1.079861,"eighty":-0.799918,"marketCap":1343551443},{"date":"2025-06-13","current":-3.979986,"twenty":-3.819658,"median":-1.125622,"eighty":-0.801093,"marketCap":1662709257},{"date":"2025-06-20","current":-3.555688,"twenty":-3.891829,"median":-1.260849,"eighty":-0.802505,"marketCap":1482539523},{"date":"2025-06-27","current":-3.398018,"twenty":-3.858555,"median":-1.338636,"eighty":-0.807993,"marketCap":1420767043},{"date":"2025-07-04","current":-3.348614,"twenty":-3.850482,"median":-1.395853,"eighty":-0.810663,"marketCap":1400176216},{"date":"2025-07-11","current":-4.33787,"twenty":-3.901653,"median":-1.565723,"eighty":-0.818449,"marketCap":1811992751},{"date":"2025-07-18","current":-4.941417,"twenty":-4.032449,"median":-1.709388,"eighty":-0.827717,"marketCap":2062485661},{"date":"2025-07-25","current":-4.84168,"twenty":-4.072278,"median":-1.830485,"eighty":-0.829191,"marketCap":2028206121},{"date":"2025-08-01","current":-4.226787,"twenty":-4.272195,"median":-1.888937,"eighty":-0.829739,"marketCap":1759683057},{"date":"2025-08-08","current":-4.394198,"twenty":-4.326025,"median":-1.964669,"eighty":-0.830438,"marketCap":1833955394},{"date":"2025-08-15","current":-4.551598,"twenty":-4.330653,"median":-2.021536,"eighty":-0.833182,"marketCap":1896801217},{"date":"2025-08-22","current":-4.428389,"twenty":-4.337848,"median":-2.077326,"eighty":-0.833612,"marketCap":1839668650},{"date":"2025-08-29","current":-6.120211,"twenty":-4.380509,"median":-2.09259,"eighty":-0.836682,"marketCap":1948220527},{"date":"2025-09-05","current":-6.359835,"twenty":-4.480886,"median":-2.122167,"eighty":-0.837164,"marketCap":2022492864},{"date":"2025-09-12","current":-7.854809,"twenty":-4.551598,"median":-2.149237,"eighty":-0.837164,"marketCap":2502406425},{"date":"2025-09-19","current":-7.860387,"twenty":-4.786316,"median":-2.153472,"eighty":-0.838292,"marketCap":2502406425},{"date":"2025-09-26","current":-7.017182,"twenty":-4.941417,"median":-2.183652,"eighty":-0.84547,"marketCap":2228170105},{"date":"2025-10-03","current":-7.036374,"twenty":-5.00868,"median":-2.202955,"eighty":-0.847167,"marketCap":2239596618},{"date":"2025-10-10","current":-6.399502,"twenty":-5.389404,"median":-2.271485,"eighty":-0.847613,"marketCap":2033919378},{"date":"2025-10-17","current":-6.134636,"twenty":-5.76051,"median":-2.316794,"eighty":-0.84775,"marketCap":1948220527},{"date":"2025-10-24","current":-6.635946,"twenty":-5.949231,"median":-2.385869,"eighty":-0.85134,"marketCap":2108191714},{"date":"2025-10-31","current":-6.715847,"twenty":-6.05096,"median":-2.429559,"eighty":-0.85508,"marketCap":2136757998},{"date":"2025-11-07","current":-5.803675,"twenty":-6.064964,"median":-2.466868,"eighty":-0.858385,"marketCap":1845381907},{"date":"2025-11-14","current":-5.357261,"twenty":-6.05096,"median":-2.479762,"eighty":-0.861761,"marketCap":1708263747},{"date":"2025-11-21","current":-5.162577,"twenty":-6.038234,"median":-2.53083,"eighty":-0.864616,"marketCap":1645417923},{"date":"2025-11-28","current":-5.001007,"twenty":-6.009542,"median":-2.552457,"eighty":-0.867916,"marketCap":1599711870},{"date":"2025-12-05","current":-5.349025,"twenty":-5.978814,"median":-2.586635,"eighty":-0.871961,"marketCap":1713977004},{"date":"2025-12-12","current":-4.983206,"twenty":-5.953787,"median":-2.601318,"eighty":-0.872449,"marketCap":1599711870},{"date":"2025-12-19","current":-4.651894,"twenty":-5.93877,"median":-2.665519,"eighty":-0.874932,"marketCap":1496873250},{"date":"2025-12-24","current":-5.398557,"twenty":-5.936744,"median":-2.679629,"eighty":-0.878314,"marketCap":1742543287},{"date":"2026-01-02","current":-5.342132,"twenty":-5.93091,"median":-2.713393,"eighty":-0.879024,"marketCap":1731116774},{"date":"2026-01-09","current":-4.766078,"twenty":-5.885949,"median":-2.738651,"eighty":-0.879423,"marketCap":1548292560},{"date":"2026-01-16","current":-4.978531,"twenty":-5.819219,"median":-2.765082,"eighty":-0.879529,"marketCap":1622564897},{"date":"2026-01-23","current":-4.878031,"twenty":-5.803991,"median":-2.784006,"eighty":-0.879587,"marketCap":1588285357},{"date":"2026-01-30","current":-4.681162,"twenty":-5.745279,"median":-2.863181,"eighty":-0.879613,"marketCap":1531152790},{"date":"2026-02-06","current":-4.617051,"twenty":-5.717934,"median":-2.968411,"eighty":-0.881855,"marketCap":1514013020},{"date":"2026-02-13","current":-4.504066,"twenty":-5.69926,"median":-3.043338,"eighty":-0.884318,"marketCap":1485446736},{"date":"2026-02-20","current":-4.579955,"twenty":-5.677229,"median":-3.125093,"eighty":-0.885389,"marketCap":1508299763}],"updateTime":1771857546429},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02511\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176040859","title":"HIGHTIDE-B Completes Phase IIb Trial of HTD1801 for Metabolic Dysfunction-Associated Steatohepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1176040859","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176040859?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:09","pubTimestamp":1770282582,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) has announced the completion of a global multicenter Phase IIb clinical study of HTD1801 in patients with metabolic dysfunction-associated steatohepatitis (MASH). The CENTRICITY...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"1138862465","title":"HighTide Therapeutics (2511) Completes Phase IIb Trial for HTD1801 in MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1138862465","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138862465?lang=en_us&edition=fundamental","pubTime":"2026-02-05 17:03","pubTimestamp":1770282180,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 2511) announced the completion of its Phase IIb global multi-regional clinical trial for HTD1801 in patients with metabolic dysfunction-associated...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"2609327844","title":"Hightide Therapeutics Completes Phase IIb Trial of HTD1801 for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2609327844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609327844?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:57","pubTimestamp":1770281859,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. announced the completion of a Phase IIb clinical study of its investigational drug HTD1801 for the treatment of metabolic dysfunction-associated steatohepatitis . The company reported that while the safety and tolerability of HTD1801 were consistent with previous studies, certain factors such as management of concomitant medications and patient compliance may have impacted the trial results. A post hoc analysis controlling for these confounding factors indicated a trend of therapeutic improvement with HTD1801 compared to placebo. HighTide Therapeutics stated that it will further evaluate its clinical development strategy for the MASH indication based on the overall data and regulatory feedback. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed. The announcement did not specify when or if the detailed study results will be presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7Y2J6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"1105617959","title":"HighTide Therapeutics (02511) Announces January 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1105617959","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105617959?lang=en_us&edition=fundamental","pubTime":"2026-02-02 17:06","pubTimestamp":1770023204,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics (02511) has disclosed its Monthly Return for the period ended 31 January 2026, confirming no changes in authorized share capital, which remains 1,000,000,000 ordinary shares at...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1171669641","title":"HighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=1171669641","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171669641?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:50","pubTimestamp":1770022234,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"2608652851","title":"HighTide Therapeutics Appoints Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608652851","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608652851?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:49","pubTimestamp":1770022192,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics  appointed Filip Surmont as chief medical officer to lead its global medical strategy, clinical development, and medical affairs, according to a Monday Hong Kong bourse filing.Surmont has more than 30 years of healthcare and pharmaceutical experience, including leadership roles at Wyeth, Pfizer, and AstraZeneca, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0122379950.USD","SG9999002224.SGD","LU1894683348.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU1066051498.USD","BK4581","BK4592","LU0170899867.USD","BK4599","LU1023059063.AUD","LENZ","LU0306807586.USD","LU0234572021.USD","BK4139","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","SG9999001176.SGD","BK4534","IE0002270589.USD","IE00B19Z3B42.SGD","BK4588","BK4550","LU0456855351.SGD","BK4568","LU0225771236.USD","SG9999013999.USD","LU0985481810.HKD","LU0868494617.USD","LU1057294990.SGD","IE00BBT3K403.USD","BK1161","BK4539","IE00B19Z3581.USD","SGXZ57979304.SGD","BK4533","02511","IE00BLSP4452.SGD","IE000M9KFDE8.USD","SG9999001176.USD","BK4007","SG9999002232.USD","LU0321505439.SGD","LU0225284248.USD","LU0306806265.USD","LU1883839398.USD","LU0321505868.SGD","BK4585"],"gpt_icon":0},{"id":"1111309360","title":"HIGHTIDE-B (02511) Appoints Dr. Filip Surmont as Chief Medical Officer to Strengthen CKM Disease Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=1111309360","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111309360?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:44","pubTimestamp":1770021859,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced the appointment of Dr. Filip Surmont as Chief Medical Officer. He will assume comprehensive responsibility for the company's medical strategy, clinical development, and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"2608483859","title":"HighTide Therapeutics Appoints Dr. Filip Surmont as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608483859","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608483859?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:37","pubTimestamp":1770021453,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. has appointed Dr. Filip Surmont as Chief Medical Officer. Dr. Surmont will oversee the company's global medical strategy, clinical development, and medical affairs, focusing on advancing HighTide's cardiovascular-kidney-metabolic  syndrome portfolio. The board currently includes Dr. LIU Liping and Ms. YU Meng as executive directors; Dr. ZHU Xun, Mr. MA Lixiong, and Mr. JIANG Feng as non-executive directors; and Mr. TAN Bo, Dr. LI Jin, and Mr. HUNG Tak Wai as independent non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL1YJLdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","BK1161"],"gpt_icon":0},{"id":"1113663532","title":"Huatai Securities International Initiates Coverage on HIGHTIDE-B (02511) with \"Buy\" Rating, Sets Target Price at HK$5.78","url":"https://stock-news.laohu8.com/highlight/detail?id=1113663532","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113663532?lang=en_us&edition=fundamental","pubTime":"2025-12-10 17:02","pubTimestamp":1765357337,"startTime":"0","endTime":"0","summary":"Huatai Securities International has released a research report initiating coverage on HIGHTIDE-B (02511), assigning a \"Buy (First-time)\" rating with a six-month target price of HK$5.78. The firm...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02511","BK1161"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00451","BK1593","06821","LU0054450605.USD","LU0823038988.USD","BK1520","LU1868837565.USD","SG9999004220.SGD","02567","09860","06069","03396","BK1116","LU0289960550.SGD","BK1117","LU0737861699.HKD","SGXZ90724238.SGD","LU2097828557.USD","IE00B8HQ1Z84.USD","IE00BQXX3F31.USD","BK1586","BK1564","LU0048597586.USD","LU0650527681.SGD","LU1366334651.USD","BK1132","BK1512","01448","LU1861219969.SGD","BK1110","BK1148","LU0320764599.SGD","01211","LU0708995583.HKD","BK1134","02453","IE00BYV24P56.USD","06633","06677","BK1186","LU1152091168.USD","IE00B0169L03.USD","02142","03650","BK1502","00999","LU1770034418.SGD","LU2506952253.HKD","BK1549","LU0516422440.USD","LU0828238088.HKD","02670","BK1096","LU0149721374.USD","09878","BK1219","81211","BK1516","IE00BGV7N243.SGD","LU0516422366.SGD","BK1608","06086","SG9999002463.SGD","BK1618","02552","BK1530","LU1981816686.USD","LU0348783233.USD","LU1251922891.USD","LU0307460666.USD","LU1770036033.HKD","LU0456827905.SGD","LU0348784397.USD","LU1861214812.USD","01458","BK1610","LU0488056044.USD","LU2663582299.SGD","02121","IE00B5MMRT66.SGD","BK1239","LU1508157978.USD","BK1544","BK1539","LU1481107354.HKD","LU1634259557.SGD","LU0431992006.USD","LU2348774022.SGD","06090","00992","BK1155","06913","LU0310800965.SGD","02696","SG9999001051.SGD","BK1233","BK1163","LU1048588211.SGD","03681","LU1497733557.USD","LU1969619763.USD","LU0588546209.SGD","BK1124","002594","06060","BK1582","IE0003851619.USD","BK1521","LU0359201885.HKD","LU2097828631.EUR","06963","IE00BZ08YT58.USD","00855","00363","02392","HK0000252152.HKD","BK1235","BK1247","00798","00020","LU0315179316.USD","LU0067412154.USD","09911","02382","02380","82020","BK1541","IE00B8L5B284.USD","02256","01276","LU0261950983.USD","ANPDY","02268","LU0072913022.USD","BK1100","IE00BPRC5H50.USD","LU1039395188.USD","02013","03896","06862","LU2106854487.HKD","BK1596","01384","BK1147","09955","HK0000306701.USD","BK1604","LU0165289439.USD","BYDDY","01318","LU2476274720.SGD","BK1141","02431","09926","BK1131","BK1504","LU0594300179.USD","02469","LU1282649067.USD","LU0175139822.USD","82331","LU1188198961.HKD","02171","LU0370786039.SGD","SG9999006597.SGD","BK1619","BK1222","09660","LU0516423091.SGD","HK0000252160.HKD","09690","LU0620787316.HKD","06919","BK1189","00884","BK1188","SG9999001093.SGD","01762","LU0049112450.USD","LU1226287529.USD","BK1214","LU0502904849.HKD","01530","BK1556","LU0348767384.USD","LU0823397103.USD","06855","02197","09927","BK1542","BK1500","LU0516423174.USD","SG9999004311.SGD","06657","LU1008478684.HKD","SG9999000418.SGD","LU1813983027.USD","LU0384037296.USD","01164","02411","LU2298064838.USD","00826","BK1160","LU1242518857.USD","BK1193","02511","BK1257","BK1215","SG9999001903.USD","LU1328615791.USD","LU0329678170.USD","IE00BD6J9T35.USD","HK0000306685.HKD","02145","BK1583","BK1606","SG9999014674.SGD","LU2008162690.USD","HK0000320264.USD","LU0143863784.USD","SGXZ86797644.SGD","LU0831093199.SGD","02157","BK1175","LU0251143458.SGD","LU0261947096.USD","86618","06608","LU0469268626.HKD","00305","03658","LU0588545730.USD","00960","01519","LU1224709979.USD","LU0762540952.USD","LU1102505929.USD","BK1526","LU1675838814.USD","LU1868837722.USD","LU0417516571.SGD","00382","LU2242644610.SGD","BK1164","IE00B543WZ88.USD","02190","BK1191","BK1253","01952","03998","LU2153592121.USD","BK1228","01818","09923","01773","06609","BK1609","LU0140636845.USD","LU0791591158.USD","LNNGY","SG9999002950.SGD","BK1230","BK1597","BK1552","LU0505663152.USD","LU0823426308.USD","LU1046422090.SGD","BK1151","LU2543165471.USD","BK1522","LU1960683339.HKD","BK1200","BK1154","BK1139","LU0449515922.USD","LU1522347837.USD","LU0107464264.USD","00003","00267","02018","LU1102505762.USD","LU0611395673.USD","LU1211504680.USD","LU0359201612.USD","LU3063872942.SGD","02315","09877","IE0003795394.USD","LU0327786744.USD","LU0287142896.SGD","BK1605","LU0593848301.USD","SG9999015978.USD","LU2357125470.USD","01681","HK0000500386.USD","LU0082770016.SGD","09992","LU1328277881.USD","SG9999002828.SGD","02565","00699","06683","BK1170","LU0048580855.USD","02167","LU0244354667.USD","BK1225","00777","BK1600","LU0164865239.USD","BK1540","BK1119","LU0348766576.USD","SG9999015945.SGD","LU0455707207.USD","LU1242518931.SGD","06058","LU0345776255.USD","LU0543330566.HKD","LU1497734951.SGD","BK1183","LU1720050803.USD","IE00BGHQDM52.EUR","02627","03145","01969","02331","LU0326950275.SGD","02556","BK1524","02858","BK1574","LU0051755006.USD","BK1589","09678","LU0348827113.USD","06186","BK1591","HYDD.SI","LU0499858438.USD","LU2097828805.USD","LU2125910500.SGD","02250","06988","LU1808992512.USD","LU0348805143.USD","02595","SG9999001226.SGD","BK1179","01735","LU1917777945.USD","00135","LU2294711713.HKD","LU2177674079.SGD","IE0008368742.USD","BK1579","LU1807302812.USD","BK1258","LU0259732245.USD","LU0511384066.AUD","02629","BK1240","01333","LU0143863198.USD","09956","SG9999006514.SGD","09996","LU0823039010.USD","BK1127","LU0634319403.HKD","LU0572939691.SGD","02551","BK1519","BK1557","BK1566","02509","BK1515","LU0572940350.SGD","BK1143","LU2348773727.SGD","IE00B0JY6N72.USD","LU0531971595.HKD","LU1880383366.USD","LU0251144936.SGD","LU2249611893.SGD","03680","LU0880133367.SGD","HK0000165453.HKD","02177","00136","BK1184","LU0417516738.SGD","IE00B031J352.USD","LU1634259391.SGD","LU2488822045.USD","02158","02057","02298","BK1140","02436","LU0164872284.USD","BK1592","02228","02616","LU0261950470.USD","IE0008369823.USD","03738","BK1220","LU0540923850.HKD","LU0043850808.USD","BK1212","LU0871576103.HKD","IE00B29SXG58.USD","LU1497733631.SGD","LU0823426480.USD","LU0856984785.SGD","BK1598","01440","LU0054237671.USD","LU0254981946.USD","BK1137","02273","SG9999000459.SGD","BK1585","02498","01177","02650","LU0588545904.SGD","BK1553","BK1144","LU1166156734.SGD","LU2328871848.SGD","02889","BK1590","LU2023250504.SGD","LU2424517915.HKD","01939","LU1235295612.USD","LU0449509016.USD","LU0173614495.USD","80992","01585","06138","BK1171","LU0348735423.USD","LU1282649810.SGD","LU0128525689.USD","LU0865486749.SGD","LU0048575426.USD","09699","LU2399975544.HKD","BK1111","BK1167","LU0531970944.HKD","LU0211977185.USD","02587","IE0009570106.USD","80020","01911","LU2153591404.USD","LU0315178854.USD","LU0819121731.USD","LU0828237510.HKD","SG9999015986.USD","02506","BK1578","BK1114","BK1595","LU0082770016.USD","LU1226287875.USD","02886","IE00BMCWC346.EUR","IE0031814852.USD","BK1161","BK1559","09919","LU0823437842.USD","LU1226288253.USD","SG9999015952.SGD","LU0417516902.SGD","BK1158","LU0572944931.SGD","00867","BK1613","06168","LU0164880469.USD","LU1939255532.USD","LU0868486357.SGD","LU0791590937.USD","LU0501845795.SGD","LNVGY","01070","LU0823397285.USD","06100","LU1226288170.HKD","01877","BK1136","01783","LU0509642566.USD","02488","LU1794554557.SGD","00300","BK1227","IE00BZ08YS42.EUR","BK1577","BK1125","BK1531","01907","00384","LU2506951792.HKD","03677","02400","LU0456846285.SGD","LU0605514214.HKD","LU1267930227.SGD","02150","09880","BK1237","02590","LU2039709279.SGD","BK1198","09961","BK1195","BK1168","LU0345775950.USD","LU1961090484.USD","SG9999000475.SGD","02279","IE00BZ08YR35.GBP","LU0463099449.HKD","BK1095","LU0228659784.USD","IE00BVYPNQ40.USD","BK1178","02155","LU0264606111.USD","LU1831875114.USD","BK1518","BK1527","06160","IE00BQXX3D17.EUR","LU0541501648.USD","BK1550","00656","LU0541502299.USD","01640","03836","BK1588","IE0032431581.USD","LU0229945570.USD","01093","BK1169","02100","BK1209","BK1224","BK1523","BK1587","LU1951186391.HKD","BK1221","LU0231483743.USD","00460","09639","01117","IE00BVYPNP33.GBP","02525","LU0737861772.HKD","LU0011963245.USD","02105","02020","LU0594300419.USD","LU2778985437.USD","01600","BK1616","LU0329678337.USD","01880","02419","BK1575","LU0269904917.USD","BK1216","BK1594","LU0348825331.USD","02276","BK1109","03709","LU0164939612.USD","HK0000320223.HKD","LU1023057109.AUD","LU2476274308.USD","BK1126","SG9999001069.SGD","00512","LU0214875030.USD","01471","BK1229","BK1548","BK1615","LU1868838027.USD","02598","09636","BK1528","LU0052750758.USD","LU0072462343.USD","LU0640798160.USD","LU1366334578.USD","01833","LU1956131251.USD","02096","SG9999011746.SGD","LU0052756011.USD","LU0702159699.USD","BK1150","LU0588545490.SGD","LU0516422952.EUR","BK1194","LU1974910355.USD","LU2097828714.EUR","02533","BK1142","LU1152091754.HKD","LU1226287792.SGD","01739","00861","LU0039217434.USD","IE00B031HY20.USD","LU0274383008.USD","LU0359202008.SGD","06613","BK1554","LU2045819591.USD","LU1880383440.USD","SG9999003461.SGD","LU0823414551.USD","BK1571","SG9999002562.SGD","00666","00017","02451","BK1607","LU0979878070.USD","IE0034224299.USD","LU1303224171.USD","LU2097828474.EUR","09959","LU0561508036.HKD","01405","BK1207","01520","09990","BK1197","LU1115378108.SGD","02460","BK1190","LU0819123356.HKD","01378","LU0499858602.USD","LU2460026573.USD","06996","LU1993786604.SGD","01809","LU0289739343.SGD","LU0314109678.HKD","LU2449936058.SGD","LU0084288322.USD","01651","06618","00302","BK1555","BK1128","LU0823414478.USD","SGXZ62798434.SGD","LU2238339852.HKD","LU2360107325.USD","09985","LU0289961442.SGD","00875","03800","03939","02420","09890","IE00BQXX3C00.GBP","LU1719994722.HKD","BK1560","BK1617","BK1104","01119","BK1509"],"gpt_icon":1},{"id":"1124992441","title":"HighTide Therapeutics (02511) Releases Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1124992441","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124992441?lang=en_us&edition=fundamental","pubTime":"2025-12-02 16:51","pubTimestamp":1764665510,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 02511) published its Monthly Return for Equity Issuer on 2 December 2025, reporting no movements in its authorised or issued share capital for November 2025....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1189634843","title":"HighTide Therapeutics (2511.HK) Reports Positive Phase III HARMONY Trial Results for HTD1801 in T2DM","url":"https://stock-news.laohu8.com/highlight/detail?id=1189634843","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189634843?lang=en_us&edition=fundamental","pubTime":"2025-12-02 08:43","pubTimestamp":1764636186,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (2511.HK) announced that HTD1801 met the primary endpoint in its Phase III HARMONY trial, a head-to-head study against dapagliflozin in patients with type 2 diabetes...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1131590371","title":"HIGHTIDE-B (02511) Announces Positive Phase III Clinical Results for HTD1801 vs. Dapagliflozin, Demonstrating Superior Glycemic Control and Cardiometabolic Benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=1131590371","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131590371?lang=en_us&edition=fundamental","pubTime":"2025-12-02 08:12","pubTimestamp":1764634343,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced positive results from its Phase III HARMONY trial (NCT06415773), a head-to-head comparison between HTD1801 and dapagliflozin in patients with type 2 diabetes (T2DM). The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","02511","BK1161","III"],"gpt_icon":0},{"id":"2588701661","title":"Hightide Therapeutics' HTD1801 Outperforms Dapagliflozin in Phase III Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701661","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588701661?lang=en_us&edition=fundamental","pubTime":"2025-12-02 08:00","pubTimestamp":1764633646,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. has announced positive topline results from its Phase III HARMONY trial evaluating HTD1801 in patients with type 2 diabetes mellitus . The study demonstrated that HTD1801 achieved the primary endpoint, showing greater HbA1c reduction and superior improvements in key cardiometabolic markers compared to dapagliflozin. These results, which have been announced by the company, reinforce the potential of HTD1801 to address metabolic drivers of T2DM progression while delivering cardiometabolic benefits. The company noted that HTD1801 has previously received two Fast Track designations and one Orphan Drug designation from the US FDA. It is not specified if the full results have been or will be presented at a scientific meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLMGZy0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"1117424956","title":"Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast","url":"https://stock-news.laohu8.com/highlight/detail?id=1117424956","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117424956?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:56","pubTimestamp":1763427395,"startTime":"0","endTime":"0","summary":"As the fourth technological revolution sweeps across the globe, with AI and large model technologies reaching critical breakthroughs, capital engines are driving the revaluation of Chinese assets at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02453","BK1163","BK1579","BK1574","BK1216","BK1585","LU1497734951.SGD","02142","09860","00382","BK1193","BK1141","BK1175","BK1207","BK1606","SG9999015945.SGD","BK1618","IE00BGHQDM52.EUR","BK1529","BK1609","LU2460026573.USD","BK1506","01907","BK1171","LU1634259391.SGD","BK1595","IE00B543WZ88.USD","BK1530","BK1556","BK1132","03658","01333","01164","06090","06919","BK1125","00003","02551","BK1500","BK1524","LU0348825331.USD","02177","BK1116","00305","LU1497733631.SGD","SG9999015978.USD","SG9999002950.SGD","02096","BK1140","01228","BK1144","BK1148","LU2476274308.USD","SG9999004220.SGD","BK1518","02670","06633","BK1194","BK1095","SG9999001069.SGD","IE00BPRC5H50.USD","00290","BK1596","03738","BK1228","LU1497733557.USD","01783","BK1613","LU1522347837.USD","02105","02533","06996","BK1188","BK1593","01651","BK1225","00867","BK1582","LU2778985437.USD","BK1587","IE00BVYPNQ40.USD","06100","BK1539","02171","BK1114","BK1191","BK1575","BK1150","BK1110","00861","BK1552","02268","09911","BK1104","00302","02157","02167","02858","BK1155","LU2476274720.SGD","06069","BK1147","BK1619","BK1202","BK1209","HK0000252160.HKD","HK0000500386.USD","IE00BVYPNP33.GBP","BK1555","BK1109","06609","SG9999003461.SGD","BK1142","02587","LU2488822045.USD","02561","06682","LU0348767384.USD","02411","02488","BK1100","BK1531","BK1583","02509","BK1219","BK1139","02627","LU0417516902.SGD","02420","00552","BK1592","BK1594","00363","03145","BK1186","09959","00826","BK1586","03315","BK1577","BK1131","BK1258","01969","02616","01809","BK1521","BK1221","BK1230","IE00BMCWC346.EUR","01762","BK1178","09878","BK1124","00604","06677","00855","06660","BK1224","BK1229","BK1161","02567","00699","02380","LU1808992512.USD","02511","BK1183","SG9999015952.SGD","01318","BK1542","LU1634259557.SGD","01167","IE00B5MMRT66.SGD","BK1137","BK1591","SG9999015986.USD","BK1608","02256","01681","02431","SG9999014674.SGD","LU0348766576.USD","HK0000252152.HKD","01773","06608","09996","02886","IE00BYV24P56.USD","BK1516","02279","00196","09678","09919","BK1527","BK1578"],"gpt_icon":0},{"id":"1183910975","title":"HighTide Therapeutics (2511) Announces HTD1801 Renal Benefit Findings at ASN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1183910975","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183910975?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:21","pubTimestamp":1762474865,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (2511) presented data at the 58th Annual Meeting of the American Society of Nephrology (ASN) in Houston, highlighting a potential renal benefit of HTD1801 in patients with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1120646221","title":"2025 ASN Breakthrough Session: HIGHTIDE-B (02511) Presents Renal Benefits Data for HTD1801","url":"https://stock-news.laohu8.com/highlight/detail?id=1120646221","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120646221?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:12","pubTimestamp":1762474334,"startTime":"0","endTime":"0","summary":"HIGHTIDE-B (02511) announced that it showcased renal benefits data for HTD1801 in patients with mild renal impairment at the 58th American Society of Nephrology (ASN) Annual Meeting in Houston, USA....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"2581031042","title":"HighTide Therapeutics Reports Positive Renal Benefit Data for HTD1801 at ASN Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581031042","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581031042?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:07","pubTimestamp":1762474074,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics Inc. has announced the presentation of new clinical evidence demonstrating the potential renal benefits of its lead asset, HTD1801, in patients with mild renal impairment. The results were presented at the 58th Annual Meeting of the American Society of Nephrology  in Houston, US. HTD1801 is described as a first-in-class anti-inflammatory metabolic modulator with dual mechanisms of AMPK activation and NLRP3 inhibition, aimed at addressing residual risks associated with cardiovascular-kidney-metabolic diseases. Data supporting these findings were derived from two randomized, double-blind, placebo-controlled Phase III studies. The company notes that HTD1801 has received two Fast Track designations and one Orphan Drug designation from the US FDA. HighTide Therapeutics cautions that there is no guarantee HTD1801 will ultimately be successfully marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL3VGjwp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02511"],"gpt_icon":0},{"id":"1162974853","title":"HighTide Therapeutics, Inc. (02511) Reports No Changes in Share Capital for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1162974853","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162974853?lang=en_us&edition=fundamental","pubTime":"2025-11-04 17:04","pubTimestamp":1762247088,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 02511) submitted a monthly return announcing that, as of October 31, 2025, total authorized share capital stood at US$100,000, with 1,000,000,000 ordinary...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0},{"id":"1199086183","title":"HighTide Therapeutics (2511) Announces Positive 52-Week Results from Phase III Trials of HTD1801 for Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=1199086183","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199086183?lang=en_us&edition=fundamental","pubTime":"2025-10-31 08:24","pubTimestamp":1761870283,"startTime":"0","endTime":"0","summary":"HighTide Therapeutics, Inc. (Stock Code: 2511) released 52-week data from two Phase III clinical trials, SYMPHONY-1 and SYMPHONY-2, evaluating its new molecular entity HTD1801 in adult patients with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}